Merck & Company, Inc. · NYSE:MRK
Merck & — JP Morgan 2016 Healthcare Conference
12 slides from Merck &'s conference presentation, Jan 11, 2016
Slide 1: JP Morgan 2016 Healthcare Conference
Merck & Co., Inc. JP MORGAN 2016 HEALTHCARE CONFERENCE January 11, 2016 Ken Frazier CHAIRMAN & CHIEF EXECUTIVE OFFICER 1
Slide 2: Forward-Looking Statement of Merck & Co., Inc.
FORWARD-LOOKING STATEMENT OF MERCK & CO., INC., KENILWORTH, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, NJ, USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995
Slide 3: Global Healthcare Market Is Evolving
Global Healthcare Market Is Evolving INCREASED CHALLENGE TO ADVANCES IN DEMAND FOR SYSTEM SCIENCE AND HEALTHCARE SUSTAINABILITY TECHNOLOGY DRIVING A FOCUS ON INNOVATION AND VALUE 3
Slide 4: Merck Has A Rich Heritage Of Bringing Groundbreaking Products To Market
Merck Has A Rich Heritage Of Bringing Groundbreaking With Potential Products To Market Future Innovations ALZHEIMER’S • MMR • INTRON A • VARIVAX • JANUVIA • KEYTRUDA AMR • PRIMAXIN • RECOMBIVAX • FOSAMAX • GARDASIL • BELSOMRA • PNEUMOVAX • ZOCOR • CRIXIVAN • ISENTRESS • VICTRELIS ATHEROSCLEROSIS • M
Slide 5: Remains Committed to Being The Premier Research-Intensive Biopharmaceutical Company
Merck Remains Committed to Being The Premier Research-Intensive Biopharmaceutical Company Innovate Pursue the most promising science to address significant unmet medical needs Adapt Execute Develop culture and business Prioritize resources to model that evolve with internal high-growth areas, key an
Slide 6: We Are Executing On Our Strategy
R&D MAJOR PRODUCT APPROVALS * We Are • KEYTRUDA, GARDASIL 9, BELSOMRA, BRIDION Executing OTHER KEY FILINGS * • Hepatitis C Doublet, Bezlotoxumab On Our ADVANCED PIPELINE * • ~20 programs advanced into Phase 2 or 3 Strategy COMMERCIAL • Continued growth of the JANUVIA franchise • Successful launch of
Slide 7: 1st Anti-PD1 To Market
• NSCLC: Approved in 2L; KN-010 data show Superior OS vs. docetaxel • Melanoma: Approved in 1L+; Superior OS vs. ipilimumab • FDA Breakthrough Therapy Designation in 3 tumor types • >10 internally-owned I/O mechanisms with several expected 1st Anti-PD1 in the clinic by YE 2016 To Market • Broadest c
Slide 8: Merck Continues to Invest in its Robust Pipeline
Merck Continues to Invest in its Robust Pipeline* Alzheimer's Disease Diabetes Mellitus Vaccines Bacterial Infection HIV Cancer Neurosciences Alzheimer's Disease Cancer Asthma Heart Failure >20 Phase I/PoC Bacterial Infection Pneumococcal Vaccine >10 Phase IIb Allergy Cancer Herpes Zoster Vaccine Al
Slide 9: Business Development Is A Key Enabler Of Our Strategy
Business Development Is A Key Enabler Of Our Strategy Early immunotherapy Adds NUC to Hospital Acute candidates HCV pipeline Care Soluble guanylate ~ 30 oncology partnerships cyclase modulators & collaborations cCam Biotherapeutics Idenix Cubist Bayer Oncology Moderna NGM … more to come Messenger No
Slide 10: Key Potential Catalysts for 2016: Anticipated Data, Filings and Approvals
Key Potential Catalysts for 2016: Anticipated Data, Filings and Approvals DATA FILINGS APPROVALS • KEYTRUDA • KEYTRUDA filings in • HCV Doublet o Registration enabling several tumor types study completions in multiple tumor types • Bezlotoxumab including 1L NSCLC • Odanacatib filing o Initial GITR d
Slide 11: Committed to Creating Long-Term Value
Committed to Creating Long-Term Value Innovate Adapt Execute 11
Slide 12: JP Morgan 2016 Healthcare Conference
Merck & Co., Inc. JP MORGAN 2016 HEALTHCARE CONFERENCE January 11, 2016 Ken Frazier CHAIRMAN & CHIEF EXECUTIVE OFFICER 12